At the Technovation event in Tashkent, Philip Morris International said it invested USD 16 billion in research, development and commercialization of less harmful alternatives for adult smokers. PMI emphasized tobacco harm reduction, noting nicotine is addictive but not the primary cause of smoking-related diseases, and seeks to grow revenue from alternatives with science-based regulation.
